Search Orphan Drug Designations and Approvals
-
Generic Name: | cedazuridine and decitabine | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Inqovi | ||||||||||||||||
Date Designated: | 08/21/2019 | ||||||||||||||||
Orphan Designation: | Treatment of myelodysplastic syndromes (including chronic myelomonocytic leukemia) | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Astex Pharmaceuticals, Inc. 4420 Rosewood Drive Suite 200 Pleasanton, California 94588 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | cedazuridine and decitabine |
---|---|---|
Trade Name: | Inqovi | |
Marketing Approval Date: | 07/07/2020 | |
Approved Labeled Indication: | Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. | |
Exclusivity End Date: | 07/07/2027 | |
Exclusivity Protected Indication* : | Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-